MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
CervoMed Inc., (NASDAQ: CRVO), formerly, Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN)*
Organization & Developments: Diffusion Pharmaceuticals
Parents
CervoMed Inc., (NASDAQ: CRVO), formerly, Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN)*
Children
*Diffusion Pharmaceuticals is actively evaluating trans sodium crocetinate (TSC)’s potential to improve the availability of oxygen in patients with COVID-19, building upon data from prior clinical studies in peripheral artery disease and glioblastoma multiform (GBM) brain cancer.
*Lead drug candidate Trans sodium crocetinate (TSC) enhances the oxygen diffusion process, supporting normal, physiologic levels of oxygen diffusion at uptake and delivery.
2024: CervoMed: H2 2024 Data For DLB Program A Major Inflection Point
2025: New Dementia Treatment Cuts Disease Progression Risk by 64% in Major Clinical Trial Success
Jumps
Finance & Acquisitions: Diffusion Pharmaceuticals
Key People: Diffusion Pharmaceuticals